NCT06920693View on ClinicalTrials.gov

Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 27, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Atopic Dermatitis (AD)
Interventions
DRUG

GB-7624

Study Drug GB-7624

DRUG

Placebo

Placebo

Trial Locations (1)

4007

RECRUITING

Generate Biomedicines Clinical Site, Herston

Sponsors
All Listed Sponsors
lead

Generate Biomedicines

INDUSTRY